ALX2004
Phase 1Small molecule
ALX2004 is one of 6 small molecule programs targeting NSCLC (Advanced Non-small Cell Lung Cancer). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in NSCLC (advanced Non-Small Cell Lung Cancer)
#DrugCompanyPhaseTrials
1Navmi
SSummit Therapeutics
Phase 2
Sacituzumab Tirumotecan
Merck & Co.Phase 2
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
NK Cells
SSouthwest Hospital, China
Preclinical
AMT-116
MMultitude Therapeutics Inc.
Preclinical
ALX2004
AALX Oncology Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALX2004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AALX Oncology Inc.